One-half of the new prescription share for Schering-Plough's loratadine product [`Claritin']

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.373, 2002-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Schering-Plough Canada finds defect in Pegetron cartridges

By  

Reactions Weekly, Vol. 1, Iss. 1324, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Schering-Plough's peginterferon (PEG IFN)- -2b plus ribavirin [Peg-Intron plus Rebetol] has been granted priority review status in Japan for a new indication

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Hepatitis C Heavyweights: Schering-Plough and Roche are Slugging it Out for Dominance in a Billion-dollar Market

By  

Pharmaceutical Innovation, Vol. 11, Iss. 3, 2002-04 ,pp. : 34-34

Adis International

Access to resources Recommend Favorite

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2b [Pegintron; Schering-Plough] has been approved by the Chinese State Food and Drug Administration for chronic hepatitis B;

By  

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite